Multimodal Recurrence Scoring System for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment - Trial NCT06032728
Access comprehensive clinical trial information for NCT06032728 through Pure Global AI's free database. This phase not specified trial is sponsored by First Affiliated Hospital, Sun Yat-Sen University and is currently Not yet recruiting. The study focuses on Renal Cell Carcinoma. Target enrollment is 488 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
First Affiliated Hospital, Sun Yat-Sen University
Timeline & Enrollment
N/A
Oct 01, 2023
Oct 01, 2033
Primary Outcome
Disease free survival
Summary
Whether patients with stage III clear cell renal cell carcinoma (ccRCC) should receive
 adjuvant targeted therapy or not is still on debate. The investigators invented a multimodal
 recurrence scoring system that was successfully categorise patients with stage III clear cell
 renal cell carcinoma into high-risk and low-risk groups with Hazard Ratio (HR) of 6.21. Here
 the investigators randomly assign assay-defined high risk patients of locally advanced ccRCC
 into adjuvant targeted therapy group and observation group. Disease free survival and overall
 survival are the end points of observation.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06032728
Non-Device Trial